secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001104659-24-090676
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants tentative approval for Liquidia's YUTREPIA but final approval delayed to May 2025 due to exclusivity
--------------------------------------------------------------------------------

- FDA granted tentative approval of YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD on Aug 19, 2024.
- Final approval delayed until after expiration of Tyvaso DPI's three-year new dosage form exclusivity on May 23, 2025.
- Liquidia plans to challenge FDA's broad grant of regulatory exclusivity to United Therapeutics for Tyvaso DPI.
- Tentative approval confirms YUTREPIA meets FDA standards for quality, safety, and efficacy but cannot be marketed yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924090676/0001104659-24-090676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924090676/tm2421912d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-090676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer